[肺癌中新辅助免疫治疗后的外科结果:阿根廷亚群中的CheckMate 816]
Alejandro Damonte1,2,3, Joaquín García Morato1, Soledad Courreges4
1División de Cirugía Torácica, Hospital de Clínicas José de San Martín, Universidad de Buenos Aires, Buenos Aires, Argentina.
Medicina
|February 3, 2025
概括
新辅助药尼沃卢马布加化疗在阿根廷的可切除非小细胞肺癌 (NSCLC) 中显示出有希望的结果. 这种治疗导致当地患者群体的完全病理反应和无病生存率高.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 胸部外科手术 胸部外科手术
背景情况:
- 检查Mate 816试验确定了新辅助药尼沃卢马布加化疗对可切除非小细胞肺癌 (NSCLC) 有效.
- 在全球范围内,这种治疗显著改善了无事件生存率和病理反应率.
研究的目的:
- 评估新辅助药尼沃卢马布加化疗在阿根廷小组NSCLC患者的疗效和安全性.
- 来自CheckMate 816研究的阿根廷患者与国际和日本亚组的结局进行比较.
主要方法:
- 一个阿根廷单一中心的回顾性观察研究 (2023年1月 - 2024年3月).
- 九名患者接受了三次新辅助尼沃卢马布 (360毫克) 加上双重化疗.
- 结果与全球和日本数据进行了比较.
主要成果:
- 在9名患者中,有8名患者接受了确定的手术,所有患者都实现了完全的 (R0) 切除.
- 三名患者 (37.5%的手术) 实现了完全的病理反应.
- 所有患者在治疗后仍然活着,并且没有疾病.
结论:
- 新辅助药尼沃卢马布加化疗在阿根廷NSCLC亚群中显示出一致的疗效和安全性.
- 完全病理反应的高率表明治疗有效性.
- 这种新辅助疗法是阿根廷患有可切除NSCLC的患者的可行选择.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.4K
07:15A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.5K
相关概念视频
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.